On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...

Nivolumab, an immune checkpoint inhibitor lauded for its groundbreaking approach to cancer treatment, marked its 10th ...

Central Valley leaders are asking voters to weigh in one of the oldest public policy questions: Which works better, the ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The US Food and Drug Administration has greenlit a new drug, marketed as Cobenfy, for oral use to treat schizophrenia in ...

September is National Recovery Month. It's dedicated to promoting treatment and recovery from alcohol and drug addiction.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

Indigenous addiction treatment centres in Alberta are delaying a program developed for the province because of a lack of ...

RelateXR uses virtual reality to help recovering addicts envision the outcome of active addiction versus long-term recovery.

California voters are considering whether to roll back some of the criminal justice reforms enacted a decade ago as concerns ...

TxGNN is the first AI model specifically developed to identify drug candidates for rare diseases and conditions with no ...

However, only few of these medications are licensed for pediatric use, indicating it may be time to reconsider the standard treatment approach ... could receive the drug for 3-6 months while ...